NCT06222580 2026-03-13
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Kura Oncology, Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Oryzon Genomics S.A.
Celgene
University of Kentucky
City of Hope Medical Center
AbbVie